Recent Updates
Recently added Catalysts

T-Cell Lymphoblastic Leukemia/Lymphoma: two biotech companies racing to a treatment

OncologyOrphan cornerData as of 2026-09-04

Competitors2in the clinic
Median market cap$374Muniverse median $1.20B
Allocated capital$149M$747M competing
Phase 3 or filed00 mid, 2 early
Pure plays0this indication only
Capital rank267/299crowding rank 100

T-Cell Lymphoblastic Leukemia/Lymphoma is a two-horse race: Artiva Biotherapeutics (ARTV, $544M) against Precision BioSciences (DTIL, $203M).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $149M of allocated capital sits on the pair.

ARTV carries 73% of the $747M competing here, so the pair is far from evenly matched.

$149M of allocated capital sits in T-Cell Lymphoblastic Leukemia/Lymphoma, ranking it 267th of 299 indications by the money committed to it.

Companies developing drugs for T-Cell Lymphoblastic Leukemia/Lymphoma 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
ARTVArtiva BiotherapeuticsGCC2005Phase 11$544MNo4 31 Dec 2028
DTILPrecision BioSciencesAnti-CD5 CAR NK cellsPhase 11$203MNo16 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. ARTV holds 73% of the $747M competing in this indication.

Why T-Cell Lymphoblastic Leukemia/Lymphoma is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. T-Cell Lymphoblastic Leukemia/Lymphoma has 2 competitors and a median of $374M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Relapsed and Refractory Multiple Myeloma1 company · $156M · median $156MUncontestedMetastatic Lung Cancer1 company · $162M · median $486MUncontestedStage IV Merkel Cell Carcinoma1 company · $134M · median $134MUncontestedAdvanced Hepatocellular Carcinoma1 company · $175M · median $175MUncontestedLeukemia1 company · $176M · median $176MUncontestedWell-differentiated Pancreatic Neuroendocrine Tumor1 company · $119M · median $356MUncontestedRecurrent Cutaneous T-Cell Lymphoma1 company · $119M · median $356MUncontestedChronic Myeloid Leukemia1 company · $180M · median $1.6BUncontested

T-Cell Lymphoblastic Leukemia/Lymphoma pipeline questions

Which biotech companies are developing drugs for T-Cell Lymphoblastic Leukemia/Lymphoma?

Artiva Biotherapeutics (ARTV, GCC2005, Phase 1); Precision BioSciences (DTIL, Anti-CD5 CAR NK cells, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in T-Cell Lymphoblastic Leukemia/Lymphoma.

How advanced is the T-Cell Lymphoblastic Leukemia/Lymphoma pipeline?

Of the 2 clinical-stage programmes in T-Cell Lymphoblastic Leukemia/Lymphoma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 2 are in early-stage development.

Which company leads the T-Cell Lymphoblastic Leukemia/Lymphoma field?

ARTV is the largest developer in T-Cell Lymphoblastic Leukemia/Lymphoma, holding 73% of the $747M of market capitalisation competing in the indication. The median competitor is worth $374M.

When is the next T-Cell Lymphoblastic Leukemia/Lymphoma catalyst?

The next dated catalyst in T-Cell Lymphoblastic Leukemia/Lymphoma is DTIL on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map